Oxyphenonium bromide | CAS# 50-10-2 (Br) | anticholinergic agent

MedKoo Cat#: 558258 | Name: Oxyphenonium bromide

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Oxyphenonium bromide is a quaternary ammonium anticholinergic agent with peripheral side effects similar to those of atropine. Oxyphenonium bromide is used as an adjunct in the treatment of gastric and duodenal ulcer, and to relieve visceral spasms. The drug has also been used in the form of eye drops for mydriatic effect.

Chemical Structure

Oxyphenonium bromide

CAS#50-10-2 (Br)

Theoretical Analysis

MedKoo Cat#: 558258

Name: Oxyphenonium bromide

CAS#: 50-10-2 (Br)

Chemical Formula: C21H34BrNO3

Exact Mass: 0.0000

Molecular Weight: 428.41

Elemental Analysis: C, 58.88; H, 8.00; Br, 18.65; N, 3.27; O, 11.20

Price and Availability

Size	Price	Availability	Quantity
1g	USD 500.00
2g	USD 800.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

50-10-2 (Br); 14214-84-7 (free base)

Synonym

50-10-2; Spasmophen; Oxifenon; Oxyfenon; Oxyphenon; Atrenyl; Bromide Oxyphenonium; Chloride, Oxyphenonium; Iodide, Oxyphenonium; Metacin; Methacin; Oxyphenon

IUPAC/Chemical Name

2-(2-cyclohexyl-2-hydroxy-2-phenylacetyl)oxyethyl-diethyl-methylazanium;bromide

InChi Key

2-(2-cyclohexyl-2-hydroxy-2-phenylacetyl)oxyethyl-diethyl-methylazanium;bromide

InChi Code

InChI=1S/C21H34NO3.BrH/c1-4-22(3,5-2)16-17-25-20(23)21(24,18-12-8-6-9-13-18)19-14-10-7-11-15-19;/h6,8-9,12-13,19,24H,4-5,7,10-11,14-17H2,1-3H3;1H/q+1;/p-1

SMILES Code

CC[N+](C)(CC)CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.[Br-]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Oxyphenonium bromide is a quaternary ammonium anticholinergic agent.

In vitro activity:

TBD

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMF	33.0	77.03
	DMSO	25.0	58.36
	Ethanol	33.0	77.03
	PBS (pH 7.2)	10.0	23.34

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 428.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: El-Gindy A, Emara S, Shaaban H. Stability-indicating method for determination of oxyphenonium bromide and its degradation product by high-performance liquid chromatography. J AOAC Int. 2007 Sep-Oct;90(5):1250-7. PMID: 17955969. 2: Funasaki N, Sumiyoshi T, Ishikawa S, Neya S. Solution structures of 1:1 complexes of oxyphenonium bromide with beta- and gamma-cyclodextrins. Mol Pharm. 2004 Mar-Apr;1(2):166-72. doi: 10.1021/mp034005p. PMID: 15832513. 3: Funasaki N, Ishikawa S, Neya S. Stoichiometric and microenvironmental effects on hydrolysis of propantheline and oxyphenonium bromides in cyclodextrin solutions. J Pharm Sci. 2001 Jun;90(6):740-8. doi: 10.1002/jps.1030. PMID: 11357177. 4: Ishikawa S. [Software development for calculation of molecular surface area and its application to hydrophobic interaction]. Yakugaku Zasshi. 2001 Jan;121(1):47-63. Japanese. doi: 10.1248/yakushi.121.47. PMID: 11201162. 5: Funasaki N, Kawaguchi R, Hada S, Neya S. Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62. doi: 10.1021/js990026s. PMID: 10430538. 6: Funasaki N, Kawaguchi R, Ishikawa S, Hada S, Neya S, Katsu T. Quantitative estimation of the bitter taste intensity of oxyphenonium bromide reduced by cyclodextrins from electromotive force measurements. Anal Chem. 1999 May 1;71(9):1733-6. doi: 10.1021/ac981286h. PMID: 21662814. 7: Joseph T, Venkataraman V, Nagarani A, David J, Bhatt A, Vaidya A. Safety pharmacology of a combination of tinidazole and oxyphenonium bromide. Arzneimittelforschung. 1997 Jul;47(7):869-72. PMID: 9272247. 8: Dharmadhikari SD, Shrivastava MP. Effects of oxyphenonium bromide and some antihistaminics (H1) on salivary flow in human volunteers. Indian J Physiol Pharmacol. 1997 Apr;41(2):183-4. PMID: 9142568. 9: Tripathi SK, Griyappanavar CR, Lal A, Biswas K, Biswas NR, Sankaranarayanan A, Sharma PL. Evaluation of antimuscarinic activity in human volunteers: a teaching aid in clinical pharmacology. Indian J Physiol Pharmacol. 1995 Apr;39(2):163-5. PMID: 7649608. 10: de Haën C, Lorusso V, Luzzani F, Tirone P. Hepatic transport of the magnetic resonance imaging contrast agent gadobenate dimeglumine in the rat. Acad Radiol. 1995 Mar;2(3):232-8. doi: 10.1016/s1076-6332(05)80171-0. PMID: 9419554. 11: Scholtmeijer RJ, van Mastrigt R. The effect of oxyphenonium bromide and oxybutynin hydrochloride on detrusor contractility and reflux in children with vesicoureteral reflux and detrusor instability. J Urol. 1991 Aug;146(2 ( Pt 2)):660-2. doi: 10.1016/s0022-5347(17)37887-4. PMID: 1907331. 12: Feitsma KG. Enantiomers of oxyphenonium bromide. Analytical and pharmacological aspects. Pharm Weekbl Sci. 1988 Oct 14;10(5):221-3. doi: 10.1007/BF01956875. PMID: 3144701. 13: Feitsma KG, Postma DS, Koëter GH, Nossent GD, Brenth BF, de Zeeuw RA. Comparative study of the bronchodilating effects of (-)- and (+)-oxyphenonium bromide. Br J Clin Pharmacol. 1988 Jun;25(6):683-7. doi: 10.1111/j.1365-2125.1988.tb05253.x. PMID: 3144299; PMCID: PMC1386444. 14: Gupta B, Singh AK, Crowell SB. A comparative study of cimetidine, ranitidine & combination of ranitidine with oxyphenonium bromide in inhibition of nocturnal gastric secretion. Indian J Med Res. 1987 Nov;86:635-40. PMID: 3132427. 15: Chaiyabutr N, Tesprateep T, Loypetjra P, Pichaicharnarong A. Urinary bladder effects after oral dosages of the antidiarrhoeal drug (clioquinol/phanquinone/oxyphenonium bromide) in experimental dogs. J Med Assoc Thai. 1985 Dec;68(12):649-53. PMID: 2937868. 16: Koëter GH, Meurs H, Jonkman JH, Greving J, Leferink J, Sluiter HJ, de Zeeuw RA, de Vries K. Protective effect of oral oxyphenonium bromide, terbutaline and theophylline against the bronchial obstructive effects of inhaled histamine, acetylcholine and propranolol. Eur J Clin Pharmacol. 1984;26(4):435-41. doi: 10.1007/BF00542137. PMID: 6329769. 17: Broor SL, Shrestha GP, Mehta SK, Sharma BK. Nocturnal gastric acid secretion in duodenal ulcer: inhibition by cimetidine. Am J Med Sci. 1981 Nov- Dec;282(3):120-4. doi: 10.1097/00000441-198111000-00004. PMID: 6797298. 18: Smajkiewicz A, Przyborowski L. Oznaczanie bromku oksyfenoniowego w preparatach farmaceutycznych z zastosowaniem elektrody jonoselektywnej [Determination of oxyphenonium bromide in pharmaceutical preparations by using ion-selective electrode]. Ann Univ Mariae Curie Sklodowska Med. 1980;35:243-9. Polish. PMID: 6817718. 19: Georgopoulos AJ, Valasidis A, Siourthas D. Treatment of chronic heart failure with slow release phentolamine. Eur J Clin Pharmacol. 1978 Jul 30;13(5):325-9. doi: 10.1007/BF00644603. PMID: 352708. 20: Greving JE, Jonkman JH, Fiks F, de Zeeuw RA, van Bork LE, Orie NG. Determination of oxyphenonium bromide in plasma and urine by means of ion-pair extraction, derivatization and gas chromatography-electron-capture detection. J Chromatogr. 1977 Nov 11;142:611-9. doi: 10.1016/s0021-9673(01)92072-2. PMID: 410817.